EUVIMEDEUVIMED entdecken
Open Access

Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma

Wenying Jiang, Maonan Wang, Xiaoqian Yu, Guoqian Liu, Xiaoyun He, Cheng Mei, Chunlin Ou

International Journal of Medical Sciences · 31.03.2025 · 22 (9) · 2040-2058

DOI: 10.7150/ijms.107255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Sciences, erschienen am 31.03.2025. Verfasst von Wenying Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China. Hauptthemen laut MEDLINE: Peroxiredoxins, Adenocarcinoma of Lung, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeroxiredoxinsAdenocarcinoma of LungAcrylamidesLung NeoplasmsAniline CompoundsHumansErbB ReceptorsDrug Resistance, NeoplasmMutationFemaleCell Line, TumorPrognosisProtein Kinase InhibitorsMaleApoptosisGene Expression Regulation, NeoplasticMiddle AgedAnimalsCell ProliferationMiceXenograft Model Antitumor AssaysBiomarkers, TumorTumor MicroenvironmentIndolesPyrimidines

Stichwörter der Autor:innen

PRDX familyimmune infiltrationimmunotherapylung adenocarcinomaprognosistherapeutic target

Substanzen

PeroxiredoxinsosimertinibErbB ReceptorsAcrylamidesAniline CompoundsEGFR protein, humanPRDX1 protein, humanProtein Kinase InhibitorsBiomarkers, TumorIndoles

Autor:innen und Institutionen

  • Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
  • Department of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, Changsha 410000, Hunan, China.
  • Departments of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
  • Department of Blood Transfusion, Xiangya Hospital, Clinical Transfusion Research Center, Central South University, Changsha 410008, Hunan, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Zitieren

APA

Jiang, W., Wang, M., Yu, X., Liu, G., He, X., Mei, C., & Ou, C. (2025). Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma. International Journal of Medical Sciences, 22(9), 2040-2058. https://doi.org/10.7150/ijms.107255

Vancouver

Jiang W, Wang M, Yu X, Liu G, He X, Mei C, et al. Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma. International Journal of Medical Sciences. 2025;22(9):2040-2058. doi:10.7150/ijms.107255

BibTeX
@article{Jiang2025,
  author = {Jiang, Wenying and Wang, Maonan and Yu, Xiaoqian and Liu, Guoqian and He, Xiaoyun and Mei, Cheng and Ou, Chunlin},
  title = {Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma},
  journal = {International Journal of Medical Sciences},
  year = {2025},
  volume = {22},
  number = {9},
  pages = {2040--2058},
  doi = {10.7150/ijms.107255}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche